Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 518-528, January 2026.Abstract Aims To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, and sodium‐glucose transport protein‐2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD).
Rong Lin +4 more
wiley +1 more source
Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes [PDF]
, 2004 Julio Rosenstock, David R. Owens
openalex +1 more source
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes [PDF]
, 2008 Julio Rosenstock +5 more
openalex +1 more source
Muscle health in the modern era of incretin‐based therapies
European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.GLP‐1 receptor agonists produce weight loss predominantly from fat mass loss, with smaller reductions in lean mass, possibly impairing muscle performance. However, newer evidence suggests muscle function and quality are preserved, potentially via improved mitochondrial efficiency, increased microvascularization and lower intramuscular fat.
Giuseppe De Girolamo +5 more
wiley +1 more source
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial [PDF]
, 2016 Julio Rosenstock +8 more
openalex +1 more source
Hemodialysis International, Volume 30, Issue 1, Page 296-301, January 2026.ABSTRACT Introduction Diabetes management in hemodialysis patients is complicated by limited treatment options and challenges in glycemic monitoring. Continuous glucose monitoring (CGM) provides detailed glucose profiles, enabling tailored glucose‐lowering therapy.
Christine L. Meyer‐Olesen +5 more
wiley +1 more source
Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.Background To observe the efficacy and safety of artificial pancreas (Android‐hybrid closed‐loop [HCL] system) in patients with type 1 diabetes mellitus (T1DM), and to compare it with insulin multi‐injection therapy. Case presentation A patient with long course of type 1 diabetes was treated with multiple injections of insulin, Android‐HCL therapy, and
Shaohua Li +9 more
wiley +1 more source
Pediatric Diabetes, Volume 2026, Issue 1, 2026.Cystic fibrosis‐related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old.
Dogus Vuralli, Andrea Scaramuzza
wiley +1 more source
Recomendaciones del Grupo GARIN para el manejo de pacientes no críticos con diabetes o hiperglucemia de estrés y nutrición artificial [PDF]
, 2012 Background & aims: By means of this update, the GARIN working group aims to define its position regarding the treatment of patients with diabetes or stress hyperglycaemia and artificial nutrition.
García Almeida, J.M. +9 more
core